Study on the Linezolid Prescription According to the Approval of Indication in a University Hospital

Autores de IIS La Fe

• Manuela Perez Cebrian

  Autor

• Isabel Font Noguera

  Autor

• Emilio Monte Boquet

  Autor

• José Luis Poveda Andrés

  Autor

• Jose Maria Martin Moreno

  Autor

• Nuria Rubio Lopez

  Autor

• Elias Ruiz Rojo

  Autor

• Agustin Llopis Gonzalez

  Autor

Participantes ajenos a IIS La Fe

• Suárez-Varela MM

Grupos

• Farmacogenética

Abstract

Indications for linezolid use are nosocomial or community-acquired pneumonia and skin infections or soft tissue infection caused by gram-positive microorganisms, but new recommendations may emerge. It is important to balance benefits with risks because severe adverse events have been described in patients taking linezolid treatment. Accordingly, we evaluated the suitability of linezolid prescription according to approval of indication by evaluating the presence of drug-related problems (DRP) in a University hospital. DRP were identified in 36 patients (50.0%). In most cases, they were related to known or established indications (15 patients, 20.8%), to safety (5 patients, 6.9%), and to both in others (16 patients, 22.2%). No DRP were recorded, which modified linezolid efficacy. DRP were significantly higher in the patients treated by an approved indication in Spain (63.3%) than in those treated by an unapproved indication in Spain (28.6%). We concluded that new studies about extending linezolid indications may be necessary.

Keywords

• Approval of indications; Drug-related problems; Drug safety evaluation; Linezolid prescription; University hospital.